MetrioPharm AG is a clinical-stage biopharmaceutical development company focused on therapies for acute and chronic inflammatory diseases. MetrioPharm is developing a novel class of self-regulating immunomodulators targeting activated macrophages and inflamed tissues.
Products, services, technology
Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting oxidative stress in immune cells.
Licensing, strategic partnerships, investments